Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients

AIDS

Volumn 24, Issue 5, 2010, Pages 707-716

  Goicoechea, Miguel ^a   Jain, Sonia ^a   Bi, Lucun ^b   Kemper, Carol ^c   Daar, Eric S ^d   Diamond, Catherine ^e   Ha, Belinda ^f   Flaherty, John ^g   Sun, Shelly ^a   Richman, Douglas ^a,h   Louie, Stan ^a   Haubrich, Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Santa Clara Valley Medical Center ^*

^c SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f GILEAD SCIENCES   (United States)

^g VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Abacavir; Antiretroviral therapy; HIV; Tenofovir; Viral decay

Indexed keywords

ABACAVIR; ADENOSINE DERIVATIVE; ANTIRETROVIRUS AGENT; CARBOVIR; CARBOVIR TRIPHOSPHATE; DEOXYADENOSINE TRIPHOSPHATE; DEOXYGUANOSINE TRIPHOSPHATE; EFAVIRENZ; LAMIVUDINE; TENOFOVIR; TENOFOVIR DIPHOSPHATE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; DEOXYGUANINE NUCLEOTIDES; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77949396499     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833676eb     Document Type: Article

References (54)

1. Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Services USDoHaH.
2. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al. Early virologic nonresponse to tenofovir, aba-cavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930.
3. Khanlou H, Yeh V, Guyer B, Farthing C. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 2005; 19:135-140.
4. Landman R, Descamps D, Peytavin G, Trylesinski A, Katlama C, Girard PM, et al. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials 2005; 6:291-301.
5. Leon A, Martinez E, Mallolas J, Laguno M, Blanco JL, Pumarola T, Gatell JM. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavir-enz or nevirapine. AIDS 2005; 19:213-215.
6. MaitlandD,Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, Gazzard B. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/ efavirenz: 12-week results from a randomized trial. AIDS 2005; 19:1183-1188.
7. Podzamczer D, Ferrer E, Gatell JM, Niubo J, Dalmau D, Leon A, et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther 2005; 10:171-177.
8. Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J. The nucleoside backbone affects durability of efa-virenz-or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr 2009; 51:140-146.
9. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, et al. Abacavir versus zidovudine combined with lamivu-dine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39:1038-1046.
10. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
11. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nu-cleotide regimens may be related. AIDS 2004; 18:2442-2444.
12. Lanier ER, Hazen R, Ross L, Freeman A, Harvey R. Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1. J Acquir Immune Defic Syndr 2005; 39:519-522.
13. Ray AS, Myrick F, Vela JE, Olson LY, Eisenberg EJ, Borroto-Esodo K, et al. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antivir Ther 2005; 10:451-457.
14. Vela JE, Miller MD, Rhodes GR, Ray AS. Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools. Antivir Ther 2008; 13:789-797.
15. Hawkins T, Veikley W, St Claire RL 3rd, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir dipho-sphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39:406-411.
16. Pruvost A, Negredo E, Theodoro F, Puig J, Levi M, Ayen R, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother 2009; 53:1937-1943.
17. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
18. Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N, et al. Determining the antiviral activity of tenofovir disoproxil fu-marate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003; 17:1151-1156.
19. Nelson PW, Mittler JE, Perelson AS. Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters. J Acquir Immune Defic Syndr 2001; 26:405-412.
20. Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lami-vudine in antiretroviral treatment-naive subjects. AIDS 1998; 12:F197-F202.
21. Mittler J, Essunger P, Yuen GJ, Clendeninn N, Markowitz M, Perelson AS. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy. Antimicrob Agents Chemother 2001; 45:1438-1443.
22. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, phar-macokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-515.
23. Louie M, Hogan C, Di Mascio M, Hurley A, Simon V, Rooney J, et al. Determining the relative efficacy of highly active anti-retroviral therapy. J Infect Dis 2003; 187:896-900.
24. Sorensen AM, Nielsen C, Mathiesen LR, Nielsen JO, Hansen JE. Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scand J Infect Dis 1993; 25:365-371.
25. Stein DS, Moore KH. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 2001; 21:11-34.
26. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleo-tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004; 37 (Suppl 1):S2-S12.
27. Havlir DV, Tierney C, Friedland GH, Pollard RB, Smeaton L, Sommadossi JP, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000; 182:321-325.
28. Holdich T, Shiveley LA, Sawyer J. Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2007; 51:2943-2947.
29. Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002; 31:45-49.
30. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent antihu-man immunodeficiency virus activity and anabolic phosphor-ylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269:12633-12638.
31. Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, et al. Steady-state pharmacokinetics of abacavir in plasma and in-tracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2009; 53:1532-1538.
32. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-266.
33. Ray AS, Olson L, Fridland A. Role of purine nucleoside phos-phorylase in interactions between 2,3-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48:1089-1095.
34. Weller S, Radomski KM, Lou Y, Stein DS. Population pharma-cokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2000; 44: 2052-2060.
35. Drusano GL, Yuen GJ, Lambert JS, Seidlin M, Dolin R, Valentine FT. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial. Ann Intern Med 1992; 116:562-566.
36. Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, et al. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir Ther 2007; 12:981-986.
37. Yegutkin GG. Nucleotide-and nucleoside-converting ectoen-zymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008; 1783:673-694.
38. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
39. Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, et al. Virologic response of zidovudine, lamivudine, and teno-fovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2006; 43:530-534.
40. Balestre E, Dupon M, Capdepont S, Thiebaut R, Boucher S, Fleury H, et al. Virological response to HIV-1 nucleoside/ nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. J Clin Virol 2006; 36:95-99.
41. Mutuluuza CK, Walker S, Kaleebu P, Robertson V, Enzama R, Burke A, et al. DART Trial. Short-term virologic response to triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART Trial. 12th Conference of Retroviruses and Opportunistic Infections. Boston, MA, USA; 22-25 February 2005.
42. Delaunay C, Brun-Vezinet F, Landman R, Collin G, Peytavin G, Trylesinski A, et al. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol 2005; 79:9572-9578.
43. GuZ,Allard B, de Muys JM, Lippens J, Rando RF, Nguyen-Ba N, et al. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcrip-tase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50:625-631.
44. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS. Unique intracellular activation of the potent antihu-man immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997; 41:1099-1107.
45. Robbins BL, Greenhaw J, Connelly MC, Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phospho-nylmethoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother 1995; 39:2304-2308.
46. Cihlar T, Ray AS, Boojamra CG, Zhang L, Hui H, Laflamme G, et al. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother 2008; 52:655-665.
47. Daluge SM, Good SS, Faletto MB, Miller WH, St Clair MH, Boone LR, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective antihuman immunodeficiency virus activity. Antimicrob Agents Chemother 1997; 41:1082-1093.
48. Nicander B, Reichard P. Relations between synthesis of deox-yribonucleotides and DNA replication in 3T6 fibroblasts. J Biol Chem 1985; 260:5376-5381.
49. Galmarini CM, Mackey JR, DumontetC.Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001; 15:875-890.
50. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor: BCX-1777. Int Immunopharmacol 2003; 3:879-887.
51. Oliver FJ, Collins MK, Lopez-Rivas A. dNTP pools imbalance as a signal to initiate apoptosis. Experientia 1996; 52:995-1000.
52. Leal DB, Streher CA, Bertoncheli Cde M, Carli LF, Leal CA, da Silva JE, et al. HIV infection is associated with increased NTPDase activity that correlates with CD39-positive lymphocytes. Biochim Biophys Acta 2005; 1746:129-134.
53. Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998; 12:1833-1844.
54. Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis 2007; 44:749-754.